Agilent Technologies Inc Stock Price, News & Analysis

Agilent Technologies Inc. (NYSE: A) has partnered with METTLER TOLEDO to enhance laboratory efficiency and accuracy in sample preparation. Their integrated solution automates the transfer of weighing results from METTLER TOLEDO's LabX Balance software to Agilent's OpenLab software, thus minimizing errors and improving workflows. This innovation aims to eliminate common transcription errors and accelerate digital transformation in labs. The collaboration was announced at Analytica 2022 in Munich and emphasizes the commitment to improving lab productivity.

Agilent Technologies reported strong Q3 2022 results, with revenue of $1.72 billion, reflecting an 8% year-over-year increase. GAAP net income reached $329 million or $1.10 EPS, a 28% increase from last year. Non-GAAP net income was $401 million with $1.34 EPS, up 22%. The company has raised its full-year revenue guidance to $6.750-$6.775 billion, indicating 6.8%-7.2% growth. Expected Q4 revenue is $1.750-$1.775 billion with non-GAAP EPS of $1.38-$1.40.

Agilent Technologies Inc. (NYSE: A) has acquired Polymer Standards Service GmbH (PSS) to enhance its offerings in polymer characterization. PSS specializes in gel permeation chromatography (GPC) and size exclusion chromatography (SEC), crucial for analyzing macromolecules. This acquisition aims to expand Agilent's product portfolio, particularly in chemical and biopharmaceutical industries. The integration will leverage Agilent’s global reach to broaden the use of PSS's technologies and products. Financial terms of the acquisition have not been disclosed.

Agilent Technologies (NYSE: A) has awarded the Agilent Thought Leader Award to Professor Gerhardt Attard from University College London for his groundbreaking research in prostate cancer using innovative liquid biopsy technologies. The award will support the identification of biomarkers related to cancer progression through analysis of circulating tumor DNA. Professor Attard expressed excitement about the potential of his research to enhance diagnostic tools for cancer treatment. Agilent's commitment to funding such research highlights its ongoing investment in advancing cancer genomics and diagnostics.

Agilent Technologies (NYSE: A) announced that Stefanos Nikolaidis, an Assistant Professor at USC Viterbi School of Engineering, received the 2022 Early Career Professor Award for his contributions to AI and Machine Vision in manufacturing. This award emphasizes Agilent's commitment to innovative technology in manufacturing, particularly in developing intuitive collaborative robots (cobots). Dr. Nikolaidis' research aims to enhance manufacturing capabilities and ensure timely delivery of high-quality scientific instruments. The company generated $6.32 billion in revenue in fiscal 2021.

Agilent Technologies (NYSE: A) has been recognized with a Top Project award for its Certified Pre-Owned Instruments Program, which reduces waste significantly. The program allows lab customers to trade in used instruments for cash or new purchases, promoting sustainability. In fiscal 2021, Agilent bought back over 900 used instruments and sold more than 3,500 certified pre-owned instruments. The initiative aligns with Agilent's commitment to net-zero emissions by 2050 and enhances their Environmental, Social and Governance (ESG) efforts.

Agilent Technologies Inc. (NYSE: A) will release its third-quarter financial results for fiscal 2022 after market close on August 16, 2022. A live webcast of the investor conference call will occur at 1:30 p.m. Pacific time on the same day. Agilent is a leader in life sciences and diagnostics, generating $6.32 billion in revenue in fiscal 2021, employing over 17,000 people globally. Investors can access the webcast via the company's investor relations website, with a replay available for 90 days.

Halo Labs, a company specializing in life science instrumentation, has successfully raised $6M in series C financing, led by Agilent Technologies. This funding will be utilized to enhance the commercialization of the Aura™ platform, expand manufacturing capacity, and develop new products targeting pharmaceutical researchers. CEO Rick Gordon expressed that this funding reflects the success of their aggressive growth strategy, noting that their instruments are now widely adopted by major biopharmaceutical firms. The Aura platform combines multiple assays into one instrument, expediting the development of new therapies.